Have a feature idea you'd love to see implemented?
Let us know!
PACB Pacific Biosciences Of California Inc
Price (delayed)
$1.97
Market cap
$539.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.46
Enterprise value
$1.38B
Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a
Highlights
The quick ratio has soared by 92% YoY and by 21% from the previous quarter
The EPS has contracted by 15% YoY but it has grown by 2.7% from the previous quarter
The revenue has decreased by 8% QoQ but it has increased by 2.1% YoY
The company's equity fell by 41% YoY and by 8% QoQ
PACB's net income is down by 28% YoY
Key stats
What are the main financial stats of PACB
Market
Valuations
Earnings
Shares outstanding
273.86M
Market cap
$539.51M
Enterprise value
$1.38B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.18
Price to sales (P/S)
3.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.98
Revenue
$173.15M
Gross profit
$36.8M
Net income
-$394.24M
EBIT
-$380.73M
EBITDA
-$326.63M
Free cash flow
-$239.56M
Per share
Balance sheet
Liquidity
EPS
-$1.46
EPS diluted
-$1.46
Free cash flow per share
-$0.88
Book value per share
$1.66
Revenue per share
$0.63
TBVPS
$2.36
Total assets
$1.45B
Total liabilities
$996.93M
Debt
$920.75M
Equity
$453.12M
Working capital
$524.24M
Debt to equity
2.03
Current ratio
9.74
Quick ratio
8.35
Net debt/EBITDA
-2.58
Margins
Efficiency
Dividend
EBITDA margin
-188.6%
Gross margin
21.3%
Net margin
-227.7%
Operating margin
-234.8%
Return on assets
-24.7%
Return on equity
-68.7%
Return on invested capital
-25.8%
Return on capital employed
-27.4%
Return on sales
-219.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PACB stock price
How has the Pacific Biosciences Of California stock price performed over time
Intraday
2.07%
1 week
0.51%
1 month
14.53%
1 year
-79.82%
YTD
-79.92%
QTD
15.88%
Financial performance
How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$173.15M
Gross profit
$36.8M
Operating income
-$406.63M
Net income
-$394.24M
Gross margin
21.3%
Net margin
-227.7%
The company's operating income fell by 29% YoY but it rose by 4.7% QoQ
PACB's net income is down by 28% YoY
PACB's operating margin is down by 26% year-on-year and by 4% since the previous quarter
The gross margin has contracted by 25% YoY and by 10% from the previous quarter
Growth
What is Pacific Biosciences Of California's growth rate over time
Valuation
What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
1.18
P/S
3.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.98
The EPS has contracted by 15% YoY but it has grown by 2.7% from the previous quarter
The P/B is 84% below the 5-year quarterly average of 7.5 and 34% below the last 4 quarters average of 1.8
The company's equity fell by 41% YoY and by 8% QoQ
The price to sales (P/S) is 86% lower than the 5-year quarterly average of 21.5 and 43% lower than the last 4 quarters average of 5.5
The revenue has decreased by 8% QoQ but it has increased by 2.1% YoY
Efficiency
How efficient is Pacific Biosciences Of California business performance
PACB's ROA is down by 48% YoY and by 5% from the previous quarter
The ROE has contracted by 48% YoY and by 12% from the previous quarter
The ROS has contracted by 22% YoY and by 4.5% from the previous quarter
The company's return on invested capital fell by 17% YoY but it rose by 6% QoQ
Dividends
What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PACB.
Financial health
How did Pacific Biosciences Of California financials performed over time
The company's total assets is 45% higher than its total liabilities
The company's current ratio has surged by 103% YoY and by 22% QoQ
The quick ratio has soared by 92% YoY and by 21% from the previous quarter
The debt is 103% greater than the equity
The company's debt to equity has surged by 66% YoY and by 8% QoQ
The company's equity fell by 41% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.